Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS: Ocriplasmin for Symptomatic Vitreomacular Adhesion
NCT01429441Phase 3Completed
- Sponsor
- Oxurion
- Start
- Oct 2011
- Primary completion
- Oct 2014
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ocriplasmin in vitreomacular adhesion (VMA), vitreomacular traction (VMT), macular hole, sponsored by Oxurion. Started Oct 2011; status: completed.
02
Drugs
ocriplasmin
03
Conditions
vitreomacular adhesion (VMA)vitreomacular traction (VMT)macular hole
Beyond the preview
Go deeper on NCT01429441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01429441.